Graham Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Graham Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104K	Sell	10,546 -8,572	-45%	-$77.7K	﹤0.01%	1149
2026 Q1	$162K	Buy	19,118 +2,614	+16%	+$24.9K	﹤0.01%	986
2025 Q4	$200K	Sell	16,504 -20,827	-56%	-$253K	﹤0.01%	1043
2025 Q3	$436K	Buy	+37,331	New	+$446K	0.01%	667
2025 Q2	–	Sell	-48,749	Closed	-$357K	–	1525
2025 Q1	$357K	Buy	48,749 +11,172	+30%	+$85.9K	0.01%	926
2024 Q4	$321K	Buy	+37,577	New	+$367K	﹤0.01%	901
2023 Q4	–	Sell	-95,363	Closed	-$299K	–	1228
2023 Q3	$299K	Buy	+95,363	New	+$390K	0.01%	725
2023 Q2	–	Sell	-77,661	Closed	-$409K	–	1207
2023 Q1	$409K	Buy	+77,661	New	+$369K	0.01%	805
2022 Q4	–	Sell	-190,121	Closed	-$789K	–	1251
2022 Q3	$789K	Buy	+190,121	New	+$958K	0.03%	585

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Graham Capital Management's OCUL Position: Q2 2026 in Review

Graham Capital Management reduced its Ocular Therapeutix (OCUL) stake by 45% in Q2 2026, selling an estimated $77.7K and leaving 10,546 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1149.

Graham Capital Management first reported a position in OCUL in Q3 2022 and has held it in 9 quarters since. The position peaked at $789K in Q3 2022. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Graham Capital Management held 10,546 shares of Ocular Therapeutix worth $104K as of Q2 2026.
Graham Capital Management sold 8,572 Ocular Therapeutix shares in Q2 2026, an estimated $77.7K.
Ocular Therapeutix made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1149 holding.
Graham Capital Management first reported a position in Ocular Therapeutix in Q3 2022 and has held it in 9 quarters since.
Graham Capital Management's Ocular Therapeutix position peaked at $789K in Q3 2022.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.